Role of surgical resection for patients with limited disease-small cell lung cancer

Tomoyoshi Takenaka, Mitsuhiro Takenoyama, Eiko Inamasu, Tsukihisa Yoshida, Gouji Toyokawa, Kaname Nosaki, Fumihiko Hirai, Masafumi Yamaguchi, Mototsugu Shimokawa, Takashi Seto, Yukito Ichinose

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Although chemotherapy and radiotherapy are recommended for patients with limited disease small cell lung cancer (LD-SCLC), several series have reported favorable survival outcomes even in patients with stages II and III disease who underwent surgical resection. The purpose of this study is to compare the outcomes of the use of surgical resection to the other conventional non-surgical treatments in patients with LD-SCLC with respect to each clinical stage. Materials and methods: We retrospectively reviewed 277 patients who received treatment for LD-SCLC and compared the outcomes of the use of surgical resection to the other conventional non-surgical treatments. Results: The clinical stage was stage I in 50 cases (18%), stage II in 53 cases (19%) and stage III in 174 cases (63%). Eighty-eight patients received surgical resection and 189 patients were treated with non-surgical treatment. Surgery was performed in 44 patients (88%) with stage I, 27 patients (52%) with stage II and 17 patients (10%) with stage III disease. The five-year survival rates of the patients according to clinical stage were 58% in stage I, 29% in stage II and 18% in stage III. The five-year survival rates of the patients with and without surgical resection according to clinical stage were as follows: 62% and 25% in stage I (. p<. 0.01), 33% and 24% in stage II (. p=. 0.95), 18% and 18% in stage III (. p=. 0.35), respectively. In 44 propensity score-matched pairs with stages II and III disease, including matching for variables such as age, gender and the PS, the five-year survival rates was better in patients with surgical resection than in those without surgery (. p=. 0.04). Conclusion: Surgical resection is effective for the patients with stage I LD-SCLC and some cases of stage II or III disease.

Original languageEnglish
Pages (from-to)52-56
Number of pages5
JournalLung Cancer
Volume88
Issue number1
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Small Cell Lung Carcinoma
Survival Rate
Propensity Score
Therapeutics
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Takenaka, T., Takenoyama, M., Inamasu, E., Yoshida, T., Toyokawa, G., Nosaki, K., ... Ichinose, Y. (2015). Role of surgical resection for patients with limited disease-small cell lung cancer. Lung Cancer, 88(1), 52-56. https://doi.org/10.1016/j.lungcan.2015.01.010

Role of surgical resection for patients with limited disease-small cell lung cancer. / Takenaka, Tomoyoshi; Takenoyama, Mitsuhiro; Inamasu, Eiko; Yoshida, Tsukihisa; Toyokawa, Gouji; Nosaki, Kaname; Hirai, Fumihiko; Yamaguchi, Masafumi; Shimokawa, Mototsugu; Seto, Takashi; Ichinose, Yukito.

In: Lung Cancer, Vol. 88, No. 1, 01.04.2015, p. 52-56.

Research output: Contribution to journalArticle

Takenaka, T, Takenoyama, M, Inamasu, E, Yoshida, T, Toyokawa, G, Nosaki, K, Hirai, F, Yamaguchi, M, Shimokawa, M, Seto, T & Ichinose, Y 2015, 'Role of surgical resection for patients with limited disease-small cell lung cancer', Lung Cancer, vol. 88, no. 1, pp. 52-56. https://doi.org/10.1016/j.lungcan.2015.01.010
Takenaka T, Takenoyama M, Inamasu E, Yoshida T, Toyokawa G, Nosaki K et al. Role of surgical resection for patients with limited disease-small cell lung cancer. Lung Cancer. 2015 Apr 1;88(1):52-56. https://doi.org/10.1016/j.lungcan.2015.01.010
Takenaka, Tomoyoshi ; Takenoyama, Mitsuhiro ; Inamasu, Eiko ; Yoshida, Tsukihisa ; Toyokawa, Gouji ; Nosaki, Kaname ; Hirai, Fumihiko ; Yamaguchi, Masafumi ; Shimokawa, Mototsugu ; Seto, Takashi ; Ichinose, Yukito. / Role of surgical resection for patients with limited disease-small cell lung cancer. In: Lung Cancer. 2015 ; Vol. 88, No. 1. pp. 52-56.
@article{2b752ad7004f49158c983b461a44fd2e,
title = "Role of surgical resection for patients with limited disease-small cell lung cancer",
abstract = "Although chemotherapy and radiotherapy are recommended for patients with limited disease small cell lung cancer (LD-SCLC), several series have reported favorable survival outcomes even in patients with stages II and III disease who underwent surgical resection. The purpose of this study is to compare the outcomes of the use of surgical resection to the other conventional non-surgical treatments in patients with LD-SCLC with respect to each clinical stage. Materials and methods: We retrospectively reviewed 277 patients who received treatment for LD-SCLC and compared the outcomes of the use of surgical resection to the other conventional non-surgical treatments. Results: The clinical stage was stage I in 50 cases (18{\%}), stage II in 53 cases (19{\%}) and stage III in 174 cases (63{\%}). Eighty-eight patients received surgical resection and 189 patients were treated with non-surgical treatment. Surgery was performed in 44 patients (88{\%}) with stage I, 27 patients (52{\%}) with stage II and 17 patients (10{\%}) with stage III disease. The five-year survival rates of the patients according to clinical stage were 58{\%} in stage I, 29{\%} in stage II and 18{\%} in stage III. The five-year survival rates of the patients with and without surgical resection according to clinical stage were as follows: 62{\%} and 25{\%} in stage I (. p<. 0.01), 33{\%} and 24{\%} in stage II (. p=. 0.95), 18{\%} and 18{\%} in stage III (. p=. 0.35), respectively. In 44 propensity score-matched pairs with stages II and III disease, including matching for variables such as age, gender and the PS, the five-year survival rates was better in patients with surgical resection than in those without surgery (. p=. 0.04). Conclusion: Surgical resection is effective for the patients with stage I LD-SCLC and some cases of stage II or III disease.",
author = "Tomoyoshi Takenaka and Mitsuhiro Takenoyama and Eiko Inamasu and Tsukihisa Yoshida and Gouji Toyokawa and Kaname Nosaki and Fumihiko Hirai and Masafumi Yamaguchi and Mototsugu Shimokawa and Takashi Seto and Yukito Ichinose",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.lungcan.2015.01.010",
language = "English",
volume = "88",
pages = "52--56",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Role of surgical resection for patients with limited disease-small cell lung cancer

AU - Takenaka, Tomoyoshi

AU - Takenoyama, Mitsuhiro

AU - Inamasu, Eiko

AU - Yoshida, Tsukihisa

AU - Toyokawa, Gouji

AU - Nosaki, Kaname

AU - Hirai, Fumihiko

AU - Yamaguchi, Masafumi

AU - Shimokawa, Mototsugu

AU - Seto, Takashi

AU - Ichinose, Yukito

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Although chemotherapy and radiotherapy are recommended for patients with limited disease small cell lung cancer (LD-SCLC), several series have reported favorable survival outcomes even in patients with stages II and III disease who underwent surgical resection. The purpose of this study is to compare the outcomes of the use of surgical resection to the other conventional non-surgical treatments in patients with LD-SCLC with respect to each clinical stage. Materials and methods: We retrospectively reviewed 277 patients who received treatment for LD-SCLC and compared the outcomes of the use of surgical resection to the other conventional non-surgical treatments. Results: The clinical stage was stage I in 50 cases (18%), stage II in 53 cases (19%) and stage III in 174 cases (63%). Eighty-eight patients received surgical resection and 189 patients were treated with non-surgical treatment. Surgery was performed in 44 patients (88%) with stage I, 27 patients (52%) with stage II and 17 patients (10%) with stage III disease. The five-year survival rates of the patients according to clinical stage were 58% in stage I, 29% in stage II and 18% in stage III. The five-year survival rates of the patients with and without surgical resection according to clinical stage were as follows: 62% and 25% in stage I (. p<. 0.01), 33% and 24% in stage II (. p=. 0.95), 18% and 18% in stage III (. p=. 0.35), respectively. In 44 propensity score-matched pairs with stages II and III disease, including matching for variables such as age, gender and the PS, the five-year survival rates was better in patients with surgical resection than in those without surgery (. p=. 0.04). Conclusion: Surgical resection is effective for the patients with stage I LD-SCLC and some cases of stage II or III disease.

AB - Although chemotherapy and radiotherapy are recommended for patients with limited disease small cell lung cancer (LD-SCLC), several series have reported favorable survival outcomes even in patients with stages II and III disease who underwent surgical resection. The purpose of this study is to compare the outcomes of the use of surgical resection to the other conventional non-surgical treatments in patients with LD-SCLC with respect to each clinical stage. Materials and methods: We retrospectively reviewed 277 patients who received treatment for LD-SCLC and compared the outcomes of the use of surgical resection to the other conventional non-surgical treatments. Results: The clinical stage was stage I in 50 cases (18%), stage II in 53 cases (19%) and stage III in 174 cases (63%). Eighty-eight patients received surgical resection and 189 patients were treated with non-surgical treatment. Surgery was performed in 44 patients (88%) with stage I, 27 patients (52%) with stage II and 17 patients (10%) with stage III disease. The five-year survival rates of the patients according to clinical stage were 58% in stage I, 29% in stage II and 18% in stage III. The five-year survival rates of the patients with and without surgical resection according to clinical stage were as follows: 62% and 25% in stage I (. p<. 0.01), 33% and 24% in stage II (. p=. 0.95), 18% and 18% in stage III (. p=. 0.35), respectively. In 44 propensity score-matched pairs with stages II and III disease, including matching for variables such as age, gender and the PS, the five-year survival rates was better in patients with surgical resection than in those without surgery (. p=. 0.04). Conclusion: Surgical resection is effective for the patients with stage I LD-SCLC and some cases of stage II or III disease.

UR - http://www.scopus.com/inward/record.url?scp=84924590157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924590157&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.01.010

DO - 10.1016/j.lungcan.2015.01.010

M3 - Article

C2 - 25662387

AN - SCOPUS:84924590157

VL - 88

SP - 52

EP - 56

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -